| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2012 | WO2012009542A2 Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration |
| 01/19/2012 | WO2012009519A1 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 01/19/2012 | WO2012009510A1 Azaindazole compounds |
| 01/19/2012 | WO2012009508A2 Microrna compositions and methods related thereto |
| 01/19/2012 | WO2012009503A1 Palatable pharmaceutical composition comprising vx-950 |
| 01/19/2012 | WO2012009475A1 Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| 01/19/2012 | WO2012009474A1 Method and formulations for treating sialic acid deficiencies |
| 01/19/2012 | WO2012009472A2 Structure, synthesis, and applications for oligo phenylene ethynylenes (opes) |
| 01/19/2012 | WO2012009447A2 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| 01/19/2012 | WO2012009446A1 Novel pyrimidinecarboxamide derivatives |
| 01/19/2012 | WO2012009402A2 Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| 01/19/2012 | WO2012009347A2 Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 |
| 01/19/2012 | WO2012009315A2 Bovine milk oligosaccharides |
| 01/19/2012 | WO2012009309A1 Compounds for the reduction of beta-amyloid production |
| 01/19/2012 | WO2012009288A2 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 01/19/2012 | WO2012009271A1 Methods of providing anticoagulation effects in subjects |
| 01/19/2012 | WO2012009263A1 Cocaine analogs and methods of preparation and uses thereof |
| 01/19/2012 | WO2012009262A2 Diclofenac salt of tramadol |
| 01/19/2012 | WO2012009227A1 Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
| 01/19/2012 | WO2012009217A1 Spirocyclic compounds |
| 01/19/2012 | WO2012009204A1 Methods for diagnosing and treating concussive disorders |
| 01/19/2012 | WO2012009194A1 Tyrosine kinase inhibitors |
| 01/19/2012 | WO2012009171A2 Compositions and methods of treatment of corneal endothelium disorders |
| 01/19/2012 | WO2012009144A2 A bioactive dose containing a material for modulating ph of a bodily fluid |
| 01/19/2012 | WO2012009134A1 Crth2 modulators |
| 01/19/2012 | WO2012008984A1 (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 01/19/2012 | WO2012008908A1 Cell therapy |
| 01/19/2012 | WO2012008845A1 Parenteral formulations of elacytarabine derivatives |
| 01/19/2012 | WO2012008788A2 Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and use thereof |
| 01/19/2012 | WO2012008765A2 Pharmaceutical composition for treating or preventing cancer |
| 01/19/2012 | WO2012008764A2 Composition for inducing multiple nuclear division of cells |
| 01/19/2012 | WO2012008718A2 Patch for treating and alleviating symptoms of skin diseases accompanied by effusion of blood proteins |
| 01/19/2012 | WO2012008711A2 Erlotinib dichloroacetate and anti-cancer agent comprising the same |
| 01/19/2012 | WO2012008697A2 Orally administered agent for increasing sperm count |
| 01/19/2012 | WO2012008675A1 Sustained-release tablet containing trimebutine |
| 01/19/2012 | WO2012008674A1 Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients |
| 01/19/2012 | WO2012008565A1 Imidazoline derivatives |
| 01/19/2012 | WO2012008564A1 Nitrogenated aromatic heterocyclic ring derivative |
| 01/19/2012 | WO2012008563A1 Nitrogenated aromatic heterocyclic ring derivative |
| 01/19/2012 | WO2012008549A1 Heterocyclic ring compound |
| 01/19/2012 | WO2012008528A1 Pyrazole compound |
| 01/19/2012 | WO2012008508A1 Heterocyclic ring compound |
| 01/19/2012 | WO2012008478A1 P2x4 receptor antagonist |
| 01/19/2012 | WO2012008474A1 Fructose absorption inhibitor |
| 01/19/2012 | WO2012008467A1 Pharmaceutical composition for promoting osteogenesis containing axial-equatorial aryl-oriented furofuran-type lignan, and pharmaceutical preparation, functional food product, and health food product comprising composition |
| 01/19/2012 | WO2012008465A1 (nucleic acid)-polysaccharide complex |
| 01/19/2012 | WO2012008457A1 Composition for external application |
| 01/19/2012 | WO2012008435A1 Biaryl amide derivative or pharmaceutically acceptable salt thereof |
| 01/19/2012 | WO2012008395A1 Substrate of three-layer structure and water-containing adhesive patch including same |
| 01/19/2012 | WO2012008317A1 Agent for promoting energy consumption |
| 01/19/2012 | WO2012008302A1 Method for preparing novel hipsc by means of mirna introduction |
| 01/19/2012 | WO2012008301A1 Method for producing novel hipsc by means of sirna introduction |
| 01/19/2012 | WO2012008231A1 4-alkylresorcinol derivative and external preparation for skin containing same |
| 01/19/2012 | WO2012008159A1 Solid dispersion of alfa-ketoamide derivatives |
| 01/19/2012 | WO2012007978A2 Fermented soya based mixture comprising isoflavones- aglicones, equol and lunasil, process for the preparation and uses thereof in food, medical and cosmetic fields. |
| 01/19/2012 | WO2012007959A1 Process for preparing dronedarone |
| 01/19/2012 | WO2012007948A2 CYTOTOXIC Ti (IV) COMPOUNDS |
| 01/19/2012 | WO2012007926A1 Substituted imidazoquinoline derivatives as kinase inhibitors |
| 01/19/2012 | WO2012007913A2 Oral administration forms for controlled release of rifampicin for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract |
| 01/19/2012 | WO2012007906A2 Eudermic compositions |
| 01/19/2012 | WO2012007886A1 Lipid bilayer carrier for drugs or imaging agents |
| 01/19/2012 | WO2012007861A1 N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| 01/19/2012 | WO2012007836A1 Pyridine compounds as sodium channel blockers |
| 01/19/2012 | WO2012007758A2 Pharmaceutical formulations |
| 01/19/2012 | WO2012007748A1 New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| 01/19/2012 | WO2012007632A1 Use of edg2 inhibitors for treating rheumatoid arthritis |
| 01/19/2012 | WO2012007627A1 Cyclic polyethers for treating and/or preventing tau- and beta-amyloid-linked neurodegenerative diseases |
| 01/19/2012 | WO2012007584A2 Composition for the treatment of superficial lesions |
| 01/19/2012 | WO2012007572A1 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them |
| 01/19/2012 | WO2012007560A1 Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue |
| 01/19/2012 | WO2012007539A1 Ip receptor agonist heterocyclic compounds |
| 01/19/2012 | WO2012007510A1 Compounds for binding and imaging amyloid plaques and their use |
| 01/19/2012 | WO2012007493A1 Purine compounds selective for ρi3κ p110 delta, and methods of use |
| 01/19/2012 | WO2012007477A1 Anti hcv oligomers |
| 01/19/2012 | WO2012007455A1 Process for the preparation of organic salts |
| 01/19/2012 | WO2012007453A1 Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol |
| 01/19/2012 | WO2012007451A1 Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol and lactic acid |
| 01/19/2012 | WO2012007416A1 Bicyclic pyrimidines |
| 01/19/2012 | WO2012007409A1 N-substituted pyrrolidines |
| 01/19/2012 | WO2012007387A1 Low- dose lithium for the treatment of neurodegenerative disorders |
| 01/19/2012 | WO2012007375A1 Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| 01/19/2012 | WO2012007367A1 New azacyclic compounds |
| 01/19/2012 | WO2012007352A1 Aqueous composition comprising bromhexine |
| 01/19/2012 | WO2012007345A2 Substituted imidazo[1,2-a]pyrimidines and -pyridines |
| 01/19/2012 | WO2012007327A1 Wogonin for the prevention and therapy of cardiac hypertrophy |
| 01/19/2012 | WO2012007150A1 Transdermal therapeutic system with a choline esterase inhibitor |
| 01/19/2012 | WO2012007138A1 Isomaltulose for use in enhancing mental performance |
| 01/19/2012 | WO2012007130A1 Treatment of lung infections by administration of tobramycin by aerolisation |
| 01/19/2012 | WO2012007008A1 Inhibitors of hdme |
| 01/19/2012 | WO2012007007A1 Inhibitors of hdme |
| 01/19/2012 | WO2012007006A1 Triazolo- and pyrazoloquinazoline derivatives as pde10a enzyme inhibitor |
| 01/19/2012 | WO2012006960A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| 01/19/2012 | WO2012006958A1 Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors |
| 01/19/2012 | WO2012006955A1 Compounds for treatment of metabolic disorders |
| 01/19/2012 | WO2012006953A1 Oxazine derivatives and their use in the treatment of neurological disorders |
| 01/19/2012 | WO2012006946A1 Anti-wssv and/or tsv nucleic acid drug |
| 01/19/2012 | WO2012006864A1 Triterpenoid saponin compounds, preparation methods and uses thereof |
| 01/19/2012 | WO2012006780A1 Phthalocyanine-serum albumin complex, method for preparation and use thereof |
| 01/19/2012 | WO2012006760A1 Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors |
| 01/19/2012 | WO2012006750A1 Nutraceutical composition obtained from fungus-challenged soy seedlings |